Creative Biolabs is at the forefront of single-domain antibody (sdAb) development, addressing the growing need for innovative therapeutic solutions. A recent study highlighted in Nature Communications demonstrated the unique ability of sdAbs to neutralize SARS-CoV-1 and -2 with high potency, showcasing their potential across various medical fields.
The company's end-to-end sdAb development solutions are designed to overcome the traditional challenges associated with antibody engineering. sdAbs, derived from camelid VHH or shark VNAR domains, offer several benefits such as deep tissue penetration, exceptional stability, rapid clearance, and low immunogenicity. These properties make them ideal for a wide range of applications, from crossing the blood-brain barrier in central nervous system treatments to serving as effective tools in imaging and theragnostic uses.
Creative Biolabs' platform enables the precise engineering of sdAb architectures, including bispecific sdAb development and multivalent sdAb engineering. These technologies allow for the creation of molecules with enhanced avidity and functional synergy, capable of targeting multiple epitopes while maintaining favorable pharmacokinetic properties. Additionally, the company provides access to a diverse recombinant sdAb library, facilitating the discovery of binders to both conventional and challenging targets.
With capabilities extending from bench to bioreactor, Creative Biolabs supports the entire development process, including high-yield expression, quality control, and downstream purification. Their work is proving crucial not only against SARS-CoV-2 variants but also in the fight against other pathogens like RSV and HIV. For more information, visit Creative Biolabs sdAb Platform.
